Complement-HIV interactions during all steps of viral pathogenesis

Vaccine

Volumn 26, Issue 24, 2008, Pages 3046-3054

  Stoiber, Heribert ^a   Banki, Zoltan ^a   Wilflingseder, Doris ^a   Dierich, Manfred P ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Complement; HIV; Retrovirus; Review

Indexed keywords

ANAPHYLATOXIN; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C5A; DECAY ACCELERATING FACTOR; GLYCOPROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; INTERLEUKIN 6; MEMBRANE COFACTOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN PRESENTING CELL; ARTICLE; CELL TRANSPORT; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DENDRITIC CELL; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOID TISSUE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; VIRUS RESISTANCE; VIRUS TRANSMISSION; VIRUS VIRULENCE;

ANAPHYLATOXINS; ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; DENDRITIC CELLS; HIV; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; LYMPHOID TISSUE; MUCOUS MEMBRANE; OPSONIN PROTEINS; VIRUS ATTACHMENT;

EID: 44649140372     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.12.003     Document Type: Article

References (102)

1. Walport M.J. Complement. First of two parts. N Engl J Med 344 (2001) 1140-1144
2. Walport M.J. Complement. Second of two parts. N Engl J Med 344 (2001) 1158-1166
3. Prodinger W.M., Würzner R., Stoiber H., and Dierich M.P. Complement. In: Paul W.E. (Ed). Fundamental immunology (2002), Lippincott-Raven Publishers, PA
4. Takeuchi Y., Cosset F.L., Lachmann P.J., Okada H., Weiss R.A., and Collins M.K. Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol 68 (1994) 8001-8007
5. Cooper N.R., Jensen F.C., Welsh R.M., and Oldstone Jr. M.B. Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med 144 (1976) 970-984
6. Bartholomew R.M., and Esser A.F. Differences in activation of human and guinea pig complement by retroviruses. J Immunol 121 (1978) 1748-1751
7. Bartholomew R.M., Esser A.F., and Muller-Eberhard H.J. Lysis of oncornaviruses by human serum. Isolation of the viral complement (C1) receptor and identification as p15E. J Exp Med 147 (1978) 844-853
8. Sherwin S.A., Benveniste R.E., and Todaro G.J. Complement-mediated lysis of type-C virus: effect of primate and human sera on various retroviruses. Int J Cancer 21 (1978) 6-11
9. Jensen F.C. Inactivation and lysis of oncornaviruses by human and primate complement. Hamatol Bluttransfus 23 (1979) 501-503
10. Kobilinsky L., Hardy Jr. W.D., Ellis R., Witkin S.S., and Day N.K. In vitro activation of feline complement by feline leukemia virus. Infect Immun 29 (1980) 165-170
11. Dierich M.P., Stoiber H., and Chen Y.M. HIV and complement. In: Gupta S. (Ed). Immunology of HIV infection (1996), Plenum Press, NY
12. Welsh Jr. R.M., Cooper N.R., Jensen F.C., and Oldstone M.B. Human serum lyses RNA tumour viruses. Nature 257 (1975) 612-614
13. Welsh Jr. R.M., Jensen F.C., Cooper N.R., and Oldstone M.B. Virology 74 (1976) 432-440
14. Takeuchi Y., Porter C.D., Strahan K.M., Preece A.F., Gustafsson K., Cosset F.L., et al. Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase. Nature 379 (1996) 85-88
15. Cooper N.R., Jensen F.C., Welsh Jr. R.M., and Oldstone M.B. Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med 144 (1976) 970-984
16. Ebenbichler C.F., Thielens N.M., Vornhagen R., Marschang P., Arlaud G.J., and Dierich M.P. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med 174 (1991) 1417-1424
17. Spear G.T., Jiang H.X., Sullivan B.L., Gewurz H., Landay A.L., and Lint T.F. Direct binding of complement component C1q to human immunodeficiency virus (HIV) and human T lymphotrophic virus-I (HTLV-I) coinfected cells. AIDS Res Hum Retroviruses 7 (1991) 579-585
18. Stoiber H., Clivio A., and Dierich M.P. Role of complement in HIV infection. Annu Rev Immunol 15 (1997) 649-674
19. Sullivan B.L., Knopoff R.J., Saiffudin M., Takefman D.M., Saarloos M.N., Sha B.E., et al. Susceptibility of HIV-1 plasma virus to complement-mediated lysis. J Immunol 157 (1996) 1791-1798
20. Dierich M.P., Stoiber H., and Clivio A. A "Complement-ary" AIDS vaccine. Nature Med 2 (1996) 153-155
21. Frank I., Stoiber H., Godar S., Möst J., Stockinger H., and Dierich M.P. Acquisition of host cell-surface-derived molecules by HIV-1. AIDS 10 (1996) 1611-1620
22. Montefiori D.C., Cornell R.J., Zhou J.Y., Zhou J.T., Hirsch V.M., and Johnson P.R. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 205 (1994) 82-92
23. Saifuddin M., Parker C.J., Peeples M.E., Gorny M.K., Zolla-Pazner S., Ghassemi M., et al. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med 182 (1995) 501-509
24. Schmitz J., Zimmer J.P., Kluxen B., Aries S., Bogel M., Gigli I., et al. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. J Clin Invest 96 (1995) 1520-1526
25. Marschang P., Sodroski J., Würzner R., and Dierich M.P. DAF protects HIV-1 from activation by complement. Eur J Immunol 25 (1995) 285-290
26. Takefman D.M., Sullivan B.L., Sha B.E., and Spear G.T. Mechanisms of resistance of HIV-1 primary isolates to complement-mediated lysis. Virology 46 (1998) 370-378
27. Stoiber H., Pintér C., Siccardi A.G., Clivio A., and Dierich M.P. Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J Exp Med 183 (1996) 307-310
28. Stoiber H., Ammann C., Spruth M., Müllauer B., Eberhart A., Harris C.L., et al. Enhancement of complement-mediated lysis by a peptide derived from SCR13 of complement factor H. Immunobiology 203 (2001) 670-686
29. Lehner T., Bergmeier L., Wang Y., Tao L., and Mitchell E. A rational basis for mucosal vaccination against HIV infection. Immunol Rev 170 (1999) 183-196
30. Hussain L.A., Kelly C., Rodin A., Jourdan M., and Lehner T. Investigation of the complement receptor 3 (CD11b/CD18) in human rectal epithelium. Clin Exp Immunol 102 (1995) 384-388
31. Cranage M.P., Baskerville A., Ashworth L.A.E., Dennis M., Cook N., Cook R., et al. Mucosal infection and vaccine studies with macaque SIV. Vaccine Res 1 (1992) 311-318
32. Lehner T., Wang Y., Cranage M., Bergmeier L., Mitchell E., Tao L., et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 2 (1996) 767-775
33. Bomsel M., and David V. Mucosal gatekeepers: selecting HIV viruses for early infection. Nat Med 8 (2002) 114-116
34. Veazey R.S., Marx P.A., and Lackner A.A. The mucosal immune system: primary target for HIV infection and AIDS. Trends Immunol 22 (2001) 626-633
35. Bouhlal H., Chomont N., Haeffner-Cavaillon N., Kazatchkine M.D., Belec L., and Hocini H. Opsonization of HIV-1 by semen complement enhances infection of human epithelial cells. J Immunol 169 (2002) 3301-3306
36. Vanderpuye O.A., Labarrere C.A., and McIntyre J.A. The complement system in human reproduction. Am J Reprod Immunol 27 (1992) 145
37. Soederholm A., Bánki Z., Wilflingseder D., Meyer M., Zwirner J., López-Trascasa M., et al. HIV-1 induced generation of C5a attracts immature DCs and promotes infection of autologous T cells. Eur J Immunol 37 (2007) 2156-2163
38. Kacani L., Bánki Z., Zwirner J., Schennach H., Baytay Z., Erdei A., et al. C5a and C5a (desArg) enhance the susceptibility of monocyte-derived macrophages to HIV infection. J Immunol 166 (2001) 3410-3415
39. Szabo R., and Short R.V. How does male circumcision protect against HIV infection?. BMJ 320 (2000) 1592-1594
40. Fleming D.T., and Wasserheit J.N. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 75 (1999) 3-17
41. Berger E.A., Doms R.W., Fenyo E.M., Korber B.T., Littman D.R., Moore J.P., et al. A new classification for HIV-1. Nature 391 (1998) 240
42. Geijtenbeek T.B., Kwon D.S., Torensma R., van Vliet S.J., van Duijnhoven G.C., Middel J., et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100 (2000) 587-597
43. Steinman R.M. DC-SIGN: a guide to some mysteries of dendritic cells. Cell 100 (2000) 491-494
44. Turville S.G., Arthos J., Donald K.M., Lynch G., Naif H., Clark G., et al. HIV gp120 receptors on human dendritic cells. Blood 98 (2001) 2482-2488
45. Guo M.M., and Hildreth J.E. HIV acquires functional adhesion receptors from host cells. AIDS Res Hum Retroviruses 11 (1995) 1007-1013
46. Ugolini S., Mondor I., and Sattentau Q.J. HIV-1 attachment: another look. Trends Microbiol 4 (1999) 144-149
47. Stoiber H., Kacani L., Speth C., Wurzner R., and Dierich M.P. The supportive role of complement in HIV pathogenesis. Immunol Rev 180 (2001) 168-176
48. Dopper S., Wilflingseder D., Prodinger W.M., Stiegler G., Speth C., Dierich M.P., et al. Mechanism(s) promoting HIV-1 infection of primary unstimulated T lymphocytes in autologous B cell/T cell co-cultures. Eur J Immunol 33 (2003) 2098-2107
49. Kacani L., Prodinger W.M., Sprinzl G.M., Schwendinger M.G., Spruth M., Stoiber H., et al. Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2. J Virol 74 (2000) 7997-8002
50. Hess C., Klimkait T., Schlapbach L., Del Zenero V., Sadallah S., Horakova E., et al. Association of a pool of HIV-1 with erythrocytes in vivo: a cohort study. Lancet 359 (2002) 2230-2234
51. Stingl G., Wolff-Schreiner E.C., Pichler W.J., Gschnait F., Knapp W., and Wolff K. Epidermal Langerhans cells bear Fc and C3 receptors. Nature 268 (1977) 245-246
52. Pruenster M., Wilflingseder D., Banki Z., Ammann C.G., Muellauer B., Meyer M., et al. C-type lectin-independent interaction of complement opsonized HIV with monocyte-derived dendritic cells. Eur J Immunol 35 (2005) 2691-2698
53. Wilflingseder D., Banki Z., Dierich M.P., and Stoiber H. Mechanisms promoting dendritic cell-mediated transmission of HIV. Mol Immunol 42 (2005) 229-237
54. Bajtay Z., Speth C., Erdei A., and Dierich M.P. Cutting edge: productive HIV-1 infection of dendritic cells via complement receptor type 3 (CR3, CD11b/CD18). J Immunol 173 (2004) 4775-4778
55. Stoiber H., Frank I., Spruth M., Schwendinger M., Mullauer B., Windisch J.M., et al. Inhibition of HIV-1 infection in vitro by monoclonal antibodies to the complement receptor type 3 (CR3): an accessory role for CR3 during virus entry?. Mol Immunol 34 (1997) 855-863
56. Stoiber H., Schneider R., Janatova J., and Dierich M.P. Human complement protein c3b, c4b, factor H and properdin react with specific sites in gp120 and gp41, the envelope proteins of HIV-1. Immunobiology 193 (1995) 98-113
57. Stoiber H., Ebenbichler C., Schneider R., Janatova J., and Dierich M.P. Interaction of several complement proteins, with gp120 and gp41, the two envelope glycoproteins of HIV-1. AIDS 9 (1995) 19-26
58. Speth C., Kacani L., and Dierich M.P. Complement receptors in HIV infection. Immunol Rev 157 (1997) 49-67
59. Thieblemont N., Haeffner-Cavaillon N., Haeffner A., Cholley B., Weiss L., and Kazatchkine M.D. Triggering of complement receptors CR1 (CD35) and CR3 (CD11b/CD18) induces nuclear translocation of NF-kappa B (p50/p65) in human monocytes and enhances viral replication in HIV-infected monocytic cells. J Immunol 155 (1995) 4861-4867
60. Wilflingseder D., Mullauer B., Schramek H., Banki Z., Pruenster M., Dierich M.P., et al. HIV-1-induced migration of monocyte-derived dendritic cells is associated with differential activation of MAPK pathways. J Immunol 173 (2004) 7497-7505
61. Geijtenbeek T.B., Koopman G., van Duijnhoven G.C., van Vliet S.J., van Schijndel A.C., Engering A., et al. Rhesus macaque and chimpanzee DC-SIGN act as HIV/SIV gp120 trans-receptors, similar to human DC-SIGN. Immunol Lett 79 (2001) 101-107
62. Doepper S., Stoiber H., Kacani L., Sprinzl G., Steindl F., Prodinger W.M., et al. B cell-mediated infection of stimulated and unstimulated autologous T lymphocytes with HIV-1: role of complement. Immunobiology 202 (2000) 293-305
63. Tenner-Racz K., Racz P., Gartner S., Ramsauer J., Dietrich M., Gluckman J.C., et al. Ultrastructural analysis of germinal centers in lymph nodes of patients with HIV-1-induced persistent generalized lymphadenopathy: evidence for persistence of infection. Prog. AIDS Pathol 1 (1989) 29-40
64. Racz P., Tenner-Racz K., and Schmidt H. Follicular dendritic cells in HIV-induced lymphadenopathy and AIDS. APMIS Suppl 8 (1989) 16-23
65. Pantaleo G., Graziosi C., Butini L., Pizzo P.A., Schnittman S.M., Kotler D.P., et al. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci USA 88 (1991) 9838-9842
66. Robertson M.N., Miyazawa M., Mori S., Caughey B., Evans L.H., Hayes S.F., et al. Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and western blotting. J Virol Methods 34 (1991) 255-271
67. Masuda A., Burton G.F., Fuchs B.A., Bhogal B.S., Rupper R., Szakal A.K., et al. Follicular dendritic cell function and murine AIDS. Immunology 81 (1994) 41-46
68. Liegler T.J., and Blair P.B. Direct detection of exogenous mouse mammary tumor virus sequences in lymphoid cells of BALB/cfC3H female mice. J Virol 59 (1986) 59-162
69. Hurtrel B., Chakrabarti L., Hurtrel M., Bach J.M., Ganiere J.P., and Montagnier L. Early events in lymph nodes during infection with SIV and FIV. Res Virol 145 (1994) 221-227
70. Chakrabarti L., Cumont M.C., Montagnier L., and Hurtrel B. Kinetics of primary SIV infection in lymph nodes. J Med Primatol 23 (1994) 117-1124
71. Stahl-Hennig C., Steinman R.M., Tenner-Racz K., Pope M., Stolte N., Matz-Rensing K., et al. Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus. Science 285 (1999) 1261-1265
72. Milush J.M., Kosub D., Marthas M., Schmidt K., Scott F., Wozniakowski A., et al. Rapid dissemination of SIV following oral inoculation. AIDS 18 (2004) 2371-2380
73. Pantaleo G., and Fauci A.S. Immunopathogenesis of HIV infection. Annu Rev Microbiol 50 (1996) 825-854
74. Haase A.T., Henry K., Zupancic M., Sedgewick G., Faust R.A., Melroe H., et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 274 (1996) 985-989
75. Joling P., Bakker L.J., Van Strijp J.A., Meerloo T., de Graaf L., Dekker M.E., et al. Binding of human immunodeficiency virus type-1 to follicular dendritic cells in vitro is complement dependent. J Immunol 150 (1993) 1065-1073
76. Heath S.L., Tew J.G., Szakal A.K., and Burton G.F. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 377 (1995) 740-744
77. Smith B.A., Gartner S., Liu Y., Perelson A.S., Stilianakis N.I., Keele B.F., et al. Persistence of infectious HIV on follicular dendritic cells. J Immunol 166 (2001) 690-696
78. Banki Z., Kacani L., Rusert P., Pruenster M., Wilflingseder D., Falkensammer B., et al. Complement dependent trapping of infectious HIV in human lymphoid tissues. AIDS 19 (2005) 481-486
79. Smith-Franklin B.A., Keele B.F., Tew J.G., Gartner S., Szakal A.K., Estes J.D., et al. Follicular dendritic cells and the persistence of HIV infectivity: the role of antibodies and Fcgamma receptors. J Immunol 168 (2002) 2408-2414
80. Fujiwara M., Tsunoda R., Shigeta S., Yokota T., and Baba M. Human follicular dendritic cells remain uninfected and capture human immunodeficiency virus type 1 through CD54-CD11a interaction. J Virol 73 (1999) 3603-3607
81. Tenner-Racz K., Racz P., Bofill M., Schulz-Meyer A., Dietrich M., Kern P., et al. HTLV-III/LAV viral antigens in lymph nodes of homosexual men with persistent generalized lymphadenopathy and AIDS. Am J Pathol 123 (1986) 9-15
82. Pantaleo G., and Fauci A.S. New concepts in the immunopathogenesis of HIV infection. Annu Rev Immunol 13 (1995) 487-512
83. Montefiori D.C., Graham B.S., Zhou J.Y., Zhou J.T., and Ahearn J.M. Binding of human immunodeficiency virus type 1 to the C3b/C4b receptor CR1 (CD35) and red blood cells in the presence of envelope-specific antibodies and complement. J Infect Dis 170 (1994) 429-432
84. Nath B.M., Schumann K.E., and Boyer J.D. The chimpanzee and other non-human-primate models in HIV-1 vaccine research. Trends Microbiol 8 (2000) 426-431
85. O'Neil S.P., Novembre F.J., Hill A.B., Suwyn C., Hart C.E., Evans-Strickfaden T., et al. Progressive infection in a subset of HIV-1-positive chimpanzees. J Infect Dis 182 (2000) 1051-1062
86. Novembre F.J., Saucier M., Anderson D.C., Klumpp S.A., O'Neil S.P., Brown II C.R., et al. Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1. J Virol 71 (1997) 4086-4091
87. Koopman G., Haaksma A.G., ten Velden J., Hack C.E., and Heeney J.L. The relative resistance of HIV type 1-infected chimpanzees to AIDS correlates with the maintenance of follicular architecture and the absence of infiltration by CD8+ cytotoxic T lymphocytes. AIDS. Res Hum Retroviruses 15 (1999) 365-373
88. Beer B., Scherer J., zur Megede J., Norley S., Baier M., and Kurth R. Lack of dichotomy between virus load of peripheral blood and lymph nodes during long-term simian immunodeficiency virus infection of African green monkeys. Virology 219 (1996) 367-375
89. Norley S.G. SIVagm infection of its natural African green monkey host. Immunol Lett 51 (1996) 53-58
90. Jakubik J.J., Saifuddin M., Takefman D.M., and Spear G.T. B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1. Immunology 96 (1999) 612-619
91. Jakubik J.J., Saifuddin M., Takefman D.M., and Spear G.T. Immune complexes containing human immunodeficiency virus type 1 primary isolates bind to lymphoid tissue B lymphocytes and are infectious for T lymphocytes. J Virol 74 (2000) 552-555
92. Zhang Z.Q., Schuler T., Cavert W., Notermans D.W., Gebhard K., Henry K., et al. Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection. Proc Natl Acad Sci USA 96 (1999) 5169-5172
93. Ledergerber B., Egger M., Erard V., Weber R., Hirschel B., Furrer H., et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 282 (1999) 2220-2226
94. Cavert W., Notermans D.W., Staskus K., Wietgrefe S.W., Zupancic M., Gebhard K., et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276 (1997) 960-964
95. Hlavachek W.S., Stilianakis N.I., and Perelson A.S. Influence of follicular dendritic cells on HIV dynamics. Philos Trans R Soc Lond 355 (2000) 1051-1058
96. Hlavachek W.S., Percus J.K., Percus O.E., Perelson A.S., and Wofsy C. Retention of antigen on follicular dendritic cells and B lymphocytes through complement-mediated multivalent ligand-receptor interactions: theory and application to HIV treatment. Math Biosci 176 (2002) 185-202
97. Popovic M., Tenner-Racz K., Pelser C., Stellbrink H.J., van Lunzen J., Lewis G., et al. Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc Natl Acad Sci USA 102 (2005) 14807-14812
98. Horakova E., Gasser O., Sadallah S., Inal J.M., Bourgeois G., Ziekau I., et al. Complement mediates the binding of HIV to erythrocytes. J Immunol 173 (2004) 4236-4241
99. Fearon D.T. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med 152 (1980) 20-30
100. Paccaud J.P., Carpentier J.L., and Schifferli J.A. Direct evidence for the clustered nature of complement receptors type 1 on the erythrocyte membrane. J Immunol 141 (1988) 3889-3894
101. Edberg J.C., Kimberly R.P., and Taylor R.P. Functional characterization of non-human primate erythrocyte immune adherence receptors: implications for the uptake of immune complexes by the cells of the mononuclear phagocytic system. Eur J Immunol 22 (1992) 1333-1339
102. Bánki Z., Wilflingseder D., Ammann C.G., Pruenster M., Müllauer B., Holländer K., et al. Factor I-mediated processing of complement-fragments on HIV immune-complexes targets HIV to CR2-expressing B cells and facilitates B cell-mediated transmission of opsonized HIV to T cells. J Immunol 177 (2006) 3469-3476